IV NAD+ therapy: a 2026 evidence review finds the wellness case unproven
·IV NAD+ has become a staple of high-end wellness and longevity clinics — marketed for energy, brain health, recovery, and anti-aging at hundreds to thousands of dollars per drip. A new narrative review in Frontiers in Aging, covering human studies from 2018 through March 2026, delivers the field's most systematic evidence check yet — and its conclusion is blunt: “current evidence regarding IV NAD+ therapy remains preliminary and insufficient to support routine clinical or wellness use.”
What the review actually found
The review's inventory of the human literature: small uncontrolled studies, observational reports, and isolated case reports — no adequately powered randomized trials of IV NAD+ for wellness endpoints. Short-term infusions raise circulating NAD+ transiently and move some biomarkers, but “the clinical significance of these findings remains uncertain,” with adverse effects including nausea, cramping, flushing, and chest discomfort. Long-term safety data: none.
The aging-premise problem
The review also undermines the premise behind much of the marketing: a large 2026 cross-sectional study found that whole-blood NAD+ concentrations were not independently associated with chronological age once disease burden was accounted for. If age alone doesn't predict NAD+ deficiency, age-bracket-based “repletion” is marketing, not medicine — trials would need to screen by actual NAD+ status.
What this doesn't mean
IV NAD+ is biochemically interesting: infused NAD+ is cleaved by enzymes like CD38 before cellular uptake, the sirtuin/PGC-1α mitochondrial-biogenesis axis is real biology, and precursor strategies may yet prove useful in targeted disease contexts. None of that equals a proven wellness intervention. If you're offered a four-figure drip, this review is the document worth asking about.
Where the evidence stands
- Established: Randomized placebo-controlled trials of IV NAD+ specifically for anti-aging or wellness indications are currently lacking — the review's central, documented finding.
- Preliminary: Small studies report transient rises in circulating NAD+ and shifts in oxidative-stress biomarkers after IV NAD+ or NMN, without established clinical significance.
- Contested: Whether whole-blood NAD+ reliably declines with healthy aging — the core premise of repletion therapy — is now disputed by large-scale human data.
- Absent: No long-term safety data for repeated IV NAD+ in wellness settings exists.